drugset / Trial / NCT06484855
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
RandomizedSequentialDouble-blindTreatment
Summary
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in primary Sjogren's syndrome (pSS) patients. This study also aims to evaluate the anti-Drug antibody after multiple ascending doses of IBI355 in pSS patients.
Timeline
- Start
- 2024-07-14
- Primary completion
- 2025-06-21
- Completion
- 2025-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBI355 | Unknown | 7.5 mg/kg | Intravenous |
| Subject | IBI355 | Unknown | 15 mg/kg | Intravenous |
| Subject | IBI355 | Unknown | 30 mg/kg | Intravenous |